Dr Marwan Kwok MB ChB, MRCP (UK), PhD, FRCPath

Dr Marwan Kwok

Institute of Cancer and Genomic Sciences
NIHR Clinical Lecturer

Contact details

Address
Institute of Cancer and Genomic Sciences
Institute for Biomedical Research West
Medical School
University of Birmingham
Edgbaston
Birmingham B15 2TT

Dr Marwan Kwok is a National Institute for Health Research (NIHR) funded clinical lecturer. He is also a specialist registrar in haematology at Queen Elizabeth Hospital Birmingham. He is a member of the Royal College of Physicians and a fellow of the Royal College of Pathologists. He held a Leukaemia and Lymphoma Research clinical research fellowship from 2014 to 2017 during which he completed doctoral research training under the mentorship of Professor Tatjana Stankovic and Professor Peter Hillmen.

His current research focuses on lymphoid malignancies, particularly chronic lymphocytic leukaemia. His research interests include the natural history and clinical heterogeneity of lymphoid malignancies, as well as novel therapeutic targets and minimal residual disease in these conditions. He has authored manuscripts in New England Journal of Medicine, Blood and Leukemia. He was an EHA-ASH Translational Research Training in Hematology (TRTH) 2015 participant, and a past recipient of the UK CLL Forum Hamblin Prize (2016, 2020) and the Royal College of Pathologists specialty research medal (March 2017). 

Qualifications

  • FRCPath, Fellowship of the Royal College of Pathologists, 2020
  • PhD, Doctor of Philosophy, University of Birmingham, 2018 
  • MRCP (UK), Membership of the Royal College of Physicians, 2013
  • MB ChB, Bachelor of Medicine and Bachelor of Surgery, University of Leeds, 2009 
  • BSc, Bachelor of Science (with first class honours), University College London, 2006

Teaching

MB ChB and BMedSc programmes

Research

Dr Kwok’s research is conducted within the Institute of Cancer and Genomic Sciences at the University of Birmingham, and at the Centre for Clinical Haematology at Queen Elizabeth Hospital. The research is carried out in close collaboration with the Haematological Malignancy Diagnostic Service in Leeds, and with the Centre for Computational Biology in Birmingham. The focus is on translational research with the aim to improve clinical outcome through novel insights into disease biology and therapeutics. Current research themes are as follows: 

1. Natural history and clinical heterogeneity of lymphoid malignancies

2. Novel therapeutic approaches for haematological malignancies and mechanisms of therapeutic resistance

3. Minimal residual disease in lymphoid malignancies

The research groups and centres that Dr Kwok has involvement with can be found at the following links:

Publications

Kwok M, Oldreive C, Rawstron AC, Goel A, Papatzikas G, Jones RE, Drennan S, Agathanggelou A, Sharma-Oates A, Evans P, Smith E, Dalal S, Mao J, Hollows R, Gordon N, Hamada M, Davies N, Parry H, Beggs AD, Munir T, Moreton P, Paneesha S, Pratt G, Taylor AMR, Forconi F, Baird DM, Cazier JB, Moss P, Hillmen P, Stankovic T. Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL. Blood. 2020; 135:411-428 

Kwok M, Rawstron AC, Varghese A, Evans PAS, O’Connor SJM, Doughty C, Newton DK, Moreton P, Hillmen P. Minimal residual disease is an independent predictor for 10-year survival in CLL. Blood. 2016; 128:2770-2773

Kwok M, Davies N, Agathanggelou A, Smith E, Oldreive C, Petermann E, Stewart G, Brown J, Lau A, Pratt G, Parry H, Taylor M, Moss P, Hillmen P, Stankovic T. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53 or ATM defective chronic lymphocytic leukemia cells. Blood. 2016; 127:582-595

Stankovic T, Kwok M. Genetics in the era of targeted CLL therapy. Blood. 2020; 135:2333-2334 

Parry HM, Mirajkar N, Cutmore N, Zuo J, Long H, Kwok M, Oldrieve C, Hudson C, Stankovic T, Paneesha S, Kelly M, Begum J, McSkeane T, Pratt G, Moss P. Long-term ibrutinib therapy reverses CD8+ T cell exhaustion in B cell chronic lymphocytic leukaemia. Front. Immunol. 2019; 10:2832

Oldreive CE, Byrd PJ, Stewart GS, Taylor AJ, Farhat S, Skowronska A, Smith E, Raghavan M, Janic D, Dokmanovic L, Clokie S, Davies N, Kwok M, Pratt G, Paneesha S, Moss P, Stankovic T, Taylor M. PALB2 variant status in hematological malignancies - a potential therapeutic target? Leuk Lymphoma. 2019; 7:1-4

Agathanggelou A, Smith E, Davies NJ, Kwok M, Zlatanou A, Oldreive CE, Mao J, Da Costa D, Yadollahi S, Perry T, Kearns P, Skowronska A, Yates E, Parry H, Hillmen P, Reverdy C, Delansorne R, Paneesha S, Pratt G, Moss P, Taylor AMR, Stewart GS, Stankovic T. USP7 inhibition alters homologous recombination repair and targets CLL cells independent of ATM/p53 functional status. Blood. 2017; 130:156-166

Davies NJ, Kwok M, Gould C, Oldreive CE, Mao J, Parry H, Smith E, Agathanggelou A, Pratt G, Taylor AMR, Moss P, Griffiths M, Stankovic T. Dynamic changes in clonal cytogenetic architecture during progression of chronic lymphocytic leukemia in patients and patient-derived murine xenografts. Oncotarget. 2017; 8:44749-44760

Rawstron AC, Bennett F, O’Connor SJM, Kwok M, Fenton JAL, Plummer M, Tute R, Richards SJ, Jack AS, Hillmen P. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. New Engl J Med. 2008; 359:575-583

Chuah C, Barnes DJ, Kwok M, Corbin A, Deininger MWN, Druker BJ, Melo JV. Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukemic cells. Leukemia. 2005; 19:1896-1904

Kwok M, Stankovic T. Targeting the Ataxia Telangiectasia and Rad3 Signaling Pathway to Overcome Chemoresistance in Cancer. In Johnson DE (ed), Targeting Cell Survival Pathways to Enhance Response to Chemotherapy. Elsevier Publishing Company. 2019; p. 204-231

Kwok M, Stankovic T. Targeting replication stress in sporadic tumors. In Grand RJ (ed), DNA Replication and Double Strand Break Repair: Mechanisms and Clinical Significance. 2018; Garland Science; p. 329-337

 

View all publications in research portal